News articles about Laboratory Corp. of America (NYSE:LH) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Laboratory Corp. of America earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.9322646034235 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
Laboratory Corp. of America stock traded down $0.08 during midday trading on Friday, hitting $164.82. 931,978 shares of the company’s stock were exchanged, compared to its average volume of 653,440. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.31 and a quick ratio of 1.20. Laboratory Corp. of America has a 12 month low of $134.19 and a 12 month high of $181.71. The stock has a market cap of $16,803.31, a price-to-earnings ratio of 17.17, a PEG ratio of 1.41 and a beta of 0.94.
Laboratory Corp. of America (NYSE:LH) last issued its earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a net margin of 12.15% and a return on equity of 16.30%. The company had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same period in the prior year, the business earned $2.15 EPS. The firm’s quarterly revenue was up 13.2% on a year-over-year basis. equities analysts expect that Laboratory Corp. of America will post 11.55 earnings per share for the current year.
LH has been the topic of a number of research analyst reports. Canaccord Genuity upped their price target on shares of Laboratory Corp. of America from $190.00 to $195.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a report on Friday, February 9th. Craig Hallum restated a “buy” rating and issued a $204.00 price target (up from $180.00) on shares of Laboratory Corp. of America in a report on Wednesday, February 7th. ValuEngine upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Goldman Sachs initiated coverage on shares of Laboratory Corp. of America in a report on Monday, January 29th. They issued a “buy” rating and a $205.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $189.19.
In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the completion of the sale, the director now directly owns 7,297 shares of the company’s stock, valued at $1,235,309.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Glenn A. Eisenberg sold 8,400 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $167.36, for a total transaction of $1,405,824.00. Following the sale, the chief financial officer now directly owns 15,931 shares of the company’s stock, valued at $2,666,212.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,630 shares of company stock valued at $9,851,701. Insiders own 0.73% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Laboratory Corp. of America (LH) Given Media Impact Score of 0.13” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/14/laboratory-corp-of-america-lh-given-media-impact-score-of-0-13.html.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.